By Daniella Parra
Creyon Bio has received a U.S. patent for its AI-driven platform that designs safer and more effective oligonucleotide-based medicines (OBMs), it said.
This company said the platform’s success includes advancing a program from concept to patient treatment in 13 months, with a high success rate in producing non-toxic compounds. Creyon also published new algorithms that enhance the design of therapeutic oligonucleotides, it said.
“These algorithms are powerful, enabling us to unravel the rules for engineering oligonucleotide-based medicines and extract maximum value from every pharmacology study we perform,” said Swagatam Mukhopadhyay, Ph.D., Co-Founder and Chief Scientific Officer of Creyon Bio. “The positive predictive value of our machine learning models built on such hyper-informative datasets is unparalleled in the industry.”
